Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lexicon Pharmaceuticals
AddedFeb 19, 2024
UpdatedJun 18, 2026
Lexicon Pharmaceuticals

Lexicon Pharmaceuticals

Public

Lexicon Pharmaceuticals, a Texas-based biopharmaceutical company, pioneers in developing treatments for human diseases since 1995.

HQ
The Woodlands, TX, US
Founded
1995
Overview
Compare
Fundraising
Employees
Website

Founded in 1995 in The Woodlands, Texas, Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to developing transformative treatments for human diseases. Co-founded by Professor Allan Bradley, FRS, and Dr. Arthur T Sands, the company leverages its patented mouse gene knockout technology and extensive in vivo screening capabilities. Lexicon focuses on therapeutic areas such as heart failure and neuropathic pain, aiming to bring innovative therapies to market through its unique approach to gene science.

Notable figures associated with Lexicon include its co-founders, Professor Allan Bradley and Dr. Arthur T Sands. The company has achieved significant milestones, including the identification of over 100 potential drug targets through its Genome5000 program. Lexicon's pioneering work has had a substantial impact on the biopharmaceutical industry, advancing precision medicine and improving patient outcomes with novel therapies.

Lexicon Pharmaceuticals - Similar Companies

Ligand Pharmaceuticals logo

Ligand Pharmaceuticals

ligand.com

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

ionispharma.com

Biolex Therapeutics logo

Biolex Therapeutics

Neurolixis logo

Neurolixis

neurolixis.com

PTC Therapeutics logo

PTC Therapeutics

ptcbio.com

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

amylyx.com

Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

kiniksa.com

Neuropathix logo

Neuropathix

neuropathix.com

Elex Biotech logo

Elex Biotech

Eikon Therapeutics logo

Eikon Therapeutics

eikontx.com

Aptinyx logo

Aptinyx

aptinyx.com

Alnylam Pharmaceuticals aln logo

Alnylam Pharmaceuticals aln

alnylam.com

KinDex Pharmaceuticals logo

KinDex Pharmaceuticals

Lumos Pharma logo

Lumos Pharma

lumos-pharma.com

Kyntra Bio logo

Kyntra Bio

fibrogen.com

Lexicon Pharmaceuticals - Quick Facts

Who are Lexicon Pharmaceuticals' competitors?

Companies similar to Lexicon Pharmaceuticals include Ligand Pharmaceuticals, Ionis Pharmaceuticals, Biolex Therapeutics and Neurolixis.

When was Lexicon Pharmaceuticals founded?

Lexicon Pharmaceuticals was founded in 1995.

Where is Lexicon Pharmaceuticals' headquarters located?

Lexicon Pharmaceuticals' headquarters is located in The Woodlands, TX, US.

When was Lexicon Pharmaceuticals' last funding round?

Lexicon Pharmaceuticals' most recent funding round was for $72.2M (USD) in June 2023.

How much has Lexicon Pharmaceuticals raised to-date?

As of Jun 20, 2023, Lexicon Pharmaceuticals has raised a total of $563.6M (USD).

How many employees does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals has 135 employees as of Feb 6, 2024.

Lexicon Pharmaceuticals - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Biotech
Unique IDs
  • ein: 760474169
  • secCik: 0001062822
  • ticker: LXRX
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 16 more industry codes
NAICS
  • 325413In-Vitro Diagnostic Substance Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2835In Vitro And In Vivo Diagnostic Substances
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research